Adaptimmune Therapeutics Plc Stock Analysis

Adaptimmune Stock Analysis Notes

About 50.0% of the company shares are held by institutions such as insurance companies. The book value of Adaptimmune Therapeutics was presently reported as 0.05. The company has Price/Earnings To Growth (PEG) ratio of 0.11. Adaptimmune Therapeutics recorded a loss per share of 0.3. The entity last dividend was issued on the 30th of March 2018. Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom. Adaptimmune Ther operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 494 people. For more info on Adaptimmune Therapeutics Plc please contact Adrian Rawcliffe at 44 12 3543 0000 or go to https://www.adaptimmune.com.

Adaptimmune Therapeutics Investment Alerts

Adaptimmune Therapeutics Upcoming and Recent Events

Adaptimmune Largest EPS Surprises

View All Earnings Estimates

Adaptimmune Therapeutics Thematic Classifications

Adaptimmune Stock Institutional Investors

Note, although Adaptimmune Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Adaptimmune Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 59.18 M.

Adaptimmune Profitablity

The company has Profit Margin (PM) of (0.4) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (20.02) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $20.02.

Management Efficiency

Adaptimmune Therapeutics has return on total asset (ROA) of (0.1239) % which means that it has lost $0.1239 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.7574) %, meaning that it created substantial loss on money invested by shareholders. Adaptimmune Therapeutics' management efficiency ratios could be used to measure how well Adaptimmune Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 03/28/2025, Return On Tangible Assets is likely to drop to -0.31. In addition to that, Return On Capital Employed is likely to drop to -0.4. At this time, Adaptimmune Therapeutics' Liabilities And Stockholders Equity is relatively stable compared to the past year. As of 03/28/2025, Non Current Liabilities Total is likely to grow to about 178.1 M, while Total Current Liabilities is likely to drop slightly above 46.5 M.

Technical Drivers

As of the 28th of March, Adaptimmune Therapeutics shows the mean deviation of 3.28, and Risk Adjusted Performance of (0.17). Adaptimmune Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.

Adaptimmune Therapeutics Price Movement Analysis

Adaptimmune Therapeutics Insider Trading Activities

Adaptimmune Therapeutics Outstanding Bonds

Adaptimmune Therapeutics Predictive Daily Indicators

Adaptimmune Therapeutics Forecast Models

Adaptimmune Therapeutics' time-series forecasting models are one of many Adaptimmune Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Adaptimmune Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Adaptimmune Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Adaptimmune shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Adaptimmune Therapeutics. By using and applying Adaptimmune Stock analysis, traders can create a robust methodology for identifying Adaptimmune entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Adaptimmune analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Adaptimmune analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Adaptimmune Therapeutics Plc stock analysis indicators help investors evaluate how Adaptimmune Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Adaptimmune Therapeutics shares will generate the highest return on investment. By understating and applying Adaptimmune Therapeutics stock analysis, traders can identify Adaptimmune Therapeutics position entry and exit signals to maximize returns.

When running Adaptimmune Therapeutics' price analysis, check to measure Adaptimmune Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptimmune Therapeutics is operating at the current time. Most of Adaptimmune Therapeutics' value examination focuses on studying past and present price action to predict the probability of Adaptimmune Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptimmune Therapeutics' price. Additionally, you may evaluate how the addition of Adaptimmune Therapeutics to your portfolios can decrease your overall portfolio volatility.